Meeting
2014 ASCO Annual Meeting
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Authors
Jaume Capdevila
Vall d'Hebron University Hospital, Barcelona, Spain
Jaume Capdevila , Jose Manuel Trigo Perez , Javier Aller , Jose Luis Manzano , Silvia Garcia Adrian , Carles Zafon , Òscar Reig , Uriel Bohn , Elena Cillan , Manuel Duran , Beatriz Gonzalez Astorga , Ana Lopez , Medina Javier , Ignacio Porras , Juan J Reina , Nuria Palacios , Enrique Grande , Juan J. Grau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 6027)
DOI
10.1200/jco.2014.32.15_suppl.6027
Abstract #
6027
Poster Bd #
43
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
First Author: Jiaying Chen
Poster
2011 ASCO Annual Meeting
17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma.
First Author: J. F. Moley
Poster
2022 ASCO Annual Meeting
Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
First Author: Aaron Scott Mansfield
Poster
2020 ASCO Virtual Scientific Program
A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).
First Author: Jochen H. Lorch